{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:04:03Z","timestamp":1790345043114,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ero.2026.100184","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:49:38Z","timestamp":1786132178000},"page":"100184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic literature review to inform the 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis: management of disease including relapse and complications"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4338","authenticated-orcid":false,"given":"Mrinalini","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga Prasanna","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Ducker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Losasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Mukhtyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Studenic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ero.2026.100184_bib0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41584-025-01309-7","article-title":"Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis","volume":"21","author":"Sawalha","year":"2025","journal-title":"Nat Rev Rheumatol."},{"issue":"10411","key":"10.1016\/j.ero.2026.100184_bib0004","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","article-title":"Polymyalgia rheumatica","volume":"402","author":"Esp\u00edgol-Frigol\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103415","article-title":"Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases?","volume":"23","author":"Salvarani","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101826","article-title":"Management of Takayasu arteritis","volume":"37","author":"Misra","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ero.2026.100184_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152677","article-title":"Aortic disease in giant cell arteritis","volume":"72","author":"Warrington","year":"2025","journal-title":"Semin Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.ero.2026.100184_bib0008","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001020","article-title":"Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis","volume":"5","author":"\u00c1gueda","year":"2019","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001003","article-title":"Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis","volume":"5","author":"Monti","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0012","first-page":"112","article-title":"Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice","volume":"38 Suppl 124","author":"Calder\u00f3n-Goercke","year":"2020","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.ero.2026.100184_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155645","article-title":"An update on the pathogenic role of IL-6 in rheumatic diseases","volume":"146","author":"Kaneko","year":"2021","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0014","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1093\/rheumatology\/keae666","article-title":"Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases","volume":"64","author":"Blanco","year":"2025","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.ero.2026.100184_bib0015","unstructured":"Cochrane Training [Internet]. Cochrane Handbook for systematic reviews of interventions. https:\/\/training.cochrane.org\/handbook."},{"key":"10.1016\/j.ero.2026.100184_bib0016","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.ero.2026.100184_bib0017","unstructured":"European Alliance of Associations for Rheumatology (EULAR). EULAR SOP. Version 54. 2025 Mar 25. www.eular.org\/document\/download\/1214\/fcccde2b-717b-4a02-9d78-e3bb5e850b5b\/1125."},{"key":"10.1016\/j.ero.2026.100184_bib0018","unstructured":"Mukhtyar C, Hellmich B, Dey M, Bartoletti A, Misra DP, Ducker G, et al. A systematic review to inform the updated EULAR guidelines on the diagnosis and management of patients with suspected giant cell arteritis, polymyalgia rheumatica, large vessel vasculitis and Takayasu arteritis. PROSPERO 2024 Available from https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024560403."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev."},{"key":"10.1016\/j.ero.2026.100184_bib0020","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. Ottawa Hospital Research Institute- Newcastle-Ottawa Scale [Internet]. Available from https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.ero.2026.100184_bib0021","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/mr\/roac157","article-title":"Clinical and angiographic outcomes of mycophenolate versus methotrexate in South Asian patients of Takayasu arteritis: results from an open-label, outcome-assessor blinded randomized controlled trial","volume":"34","author":"Padiyar","year":"2023","journal-title":"Mod Rheumatol."},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0023","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/kead387","article-title":"Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study","volume":"63","author":"Wang","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0024","doi-asserted-by":"crossref","first-page":"rkaf013","DOI":"10.1093\/rap\/rkaf013","article-title":"Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis","volume":"9","author":"Yoshifuji","year":"2025","journal-title":"Rheumatol Adv Pract"},{"issue":"9","key":"10.1016\/j.ero.2026.100184_bib0025","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Nakaoka","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"issue":"11","key":"10.1016\/j.ero.2026.100184_bib0026","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/clc.23439","article-title":"Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: a randomized parallel controlled clinical trial","volume":"43","author":"Li","year":"2020","journal-title":"Clin Cardiol."},{"key":"10.1016\/j.ero.2026.100184_bib0027","first-page":"suppl 9","article-title":"Comparison of mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for active Takayasu\u2019s arteritis: an open-label, randomized-controlled trial [abstract]","volume":"76","author":"Sun","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.ero.2026.100184_bib0028","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.ard.2025.07.018","article-title":"Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis","volume":"84","author":"Sun","year":"2025","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ero.2026.100184_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320922019","article-title":"Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study","volume":"11","author":"Dai","year":"2020","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.ero.2026.100184_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320975233","article-title":"Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis","volume":"11","author":"Wu","year":"2020","journal-title":"Ther Adv Chronic Dis."},{"key":"10.1016\/j.ero.2026.100184_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152446","article-title":"Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis","volume":"66","author":"Kaymaz-Tahra","year":"2024","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103275","article-title":"The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu arteritis: a systematic review and meta-analysis","volume":"22","author":"Misra","year":"2023","journal-title":"Autoimmun Rev."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0033","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.semarthrit.2021.09.010","article-title":"Biologic treatments in Takayasu's arteritis: a comparative study of tumor necrosis factor inhibitors and tocilizumab","volume":"51","author":"Alibaz-Oner","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0034","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.semarthrit.2020.01.005","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis","volume":"50","author":"Campochiaro","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/mr\/roab012","article-title":"Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: a real-life experience from a monocentric cohort","volume":"32","author":"Tomelleri","year":"2022","journal-title":"Mod Rheumatol."},{"issue":"8","key":"10.1016\/j.ero.2026.100184_bib0036","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.42496","article-title":"Comparative Efficacy of secukinumab versus tumor necrosis factor inhibitors for the treatment of Takayasu arteritis","volume":"75","author":"Tian","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0037","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","article-title":"Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients","volume":"61","author":"Mekinian","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2026.100184_bib0038","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/rmdopen-2022-002830","article-title":"Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study","volume":"9","author":"Mekinian","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2026.100184_bib0039","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2018.04.002","article-title":"Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients","volume":"91","author":"Mekinian","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ero.2026.100184_bib0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijcard.2017.12.066","article-title":"Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide","volume":"266","author":"Kong","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0041","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2026.100184_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study","volume":"55","author":"Wang","year":"2022","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ero.2026.100184_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2023-003992","article-title":"Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study","volume":"10","author":"Peron Filho","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2026.100184_bib0044","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2019.02.046","article-title":"Statins reduce relapse rate in Takayasu arteritis","volume":"287","author":"Kwon","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ero.2026.100184_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.723506","article-title":"A prospective observational study on the efficacy and safety of infliximab-biosimilar (CT-P13) in patients with Takayasu arteritis (TAKASIM)","volume":"8","author":"Campochiaro","year":"2021","journal-title":"Front Med."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0046","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semarthrit.2019.06.009","article-title":"Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort","volume":"50","author":"Cui","year":"2019","journal-title":"Semin Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.ero.2026.100184_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102634","article-title":"Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study","volume":"19","author":"Mertz","year":"2020","journal-title":"Autoimmun Rev."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0048","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","article-title":"Efficacy of leflunomide in the treatment of vasculitis","author":"Mustapha","year":"2021","journal-title":"Clin Exp Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0049","doi-asserted-by":"crossref","first-page":"135","DOI":"10.55563\/clinexprheumatol\/z6drbj","article-title":"The effects of biological agents on vascular structural lesions in Takayasu's arteritis","volume":"39 Suppl 129","author":"Erbasan","year":"2021","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105186","article-title":"Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: a prospective cohort study in a Chinese population","volume":"88","author":"Wu","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0051","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/mr\/roac099","article-title":"A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: the ACTEMRA\u00ae (ACT)-Bridge study","volume":"33","author":"Harigai","year":"2023","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.ero.2026.100184_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.12.005","article-title":"Cessation of immunosuppressive therapies in patients with Takayasu arteritis with sustained inactive disease","volume":"52","author":"Ross","year":"2022","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3899\/jrheum.181222","article-title":"Effect of treatment on imaging, clinical, and serologic assessments of disease activity in large-vessel vasculitis","volume":"47","author":"Banerjee","year":"2020","journal-title":"J Rheumatol"},{"issue":"S1","key":"10.1016\/j.ero.2026.100184_bib0054","first-page":"623","article-title":"Stenting for middle aortic syndrome caused by Takayasu arteritis-immediate and long-term outcomes","volume":"91","author":"Che","year":"2018","journal-title":"Catheter Cardiovasc Interv."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0055","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/1526602819874474","article-title":"Endovascular treatment of iliac artery stenosis caused by Takayasu arteritis: a 10-Year experience","volume":"26","author":"Dong","year":"2019","journal-title":"J Endovasc Ther."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0056","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/08941939.2017.1408718","article-title":"Treatment with corticosteroid and\/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu's arteritis","volume":"32","author":"Zheng","year":"2019","journal-title":"J Invest Surg."},{"key":"10.1016\/j.ero.2026.100184_bib0057","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.avsg.2019.07.009","article-title":"Surgery and endovascular management in patients with Takayasu's arteritis: a ten-year retrospective study","volume":"63","author":"Diao","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ero.2026.100184_bib0058","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.avsg.2023.12.074","article-title":"Outcome of open repair of thoracoabdominal aortic aneurysm in Takayasu arteritis: a retrospective analysis","volume":"103","author":"Sun","year":"2024","journal-title":"Ann Vasc Surg"},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0059","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ejvs.2018.02.030","article-title":"Endovascular versus open surgical intervention in patients with Takayasu's arteritis: a meta-analysis","volume":"55","author":"Jung","year":"2018","journal-title":"Eur J Vasc Endovasc Surg."},{"issue":"29","key":"10.1016\/j.ero.2026.100184_bib0060","doi-asserted-by":"crossref","first-page":"e7558","DOI":"10.1097\/MD.0000000000007558","article-title":"Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: a meta-analysis","volume":"96","author":"Jeong","year":"2017","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0061","doi-asserted-by":"crossref","first-page":"rky026","DOI":"10.1093\/rap\/rky026","article-title":"Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study","volume":"2","author":"Baldwin","year":"2018","journal-title":"Rheumatol Adv Pract."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0062","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10067-023-06829-9","article-title":"Renal artery involvement is associated with increased morbidity but not mortality in Takayasu arteritis: a matched cohort study of 215 patients","volume":"43","author":"Thakare","year":"2024","journal-title":"Clin Rheumatol."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0063","first-page":"161","article-title":"The results of treatment in renal artery stenosis due to Takayasu disease: comparison between surgery, angioplasty, and stenting. A monocentrique retrospective study","volume":"36","author":"Kinjo","year":"2015","journal-title":"G Chir."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0064","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3899\/jrheum.190965","article-title":"Characteristics and medium-term outcomes of Takayasu arteritis-related renal artery stenosis: analysis of a large Chinese cohort","volume":"48","author":"Sun","year":"2021","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2026.100184_bib0065","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s10067-017-3947-4","article-title":"The presentation and management of hypertension in a large cohort of Takayasu arteritis","volume":"37","author":"Qi","year":"2018","journal-title":"Clin Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0066","first-page":"46","article-title":"Cardiopulmonary involvement in Takayasu's arteritis","author":"Brennan","year":"2018","journal-title":"Clin Exp Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0067","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3899\/jrheum.190045","article-title":"Pulmonary artery involvement in patients with Takayasu arteritis","volume":"47","author":"He","year":"2020","journal-title":"J Rheumatol."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0068","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13075-020-02203-1","article-title":"Involvement of the pulmonary arteries in patients with Takayasu arteritis: a prospective study from a single centre in China","volume":"22","author":"Kong","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.ero.2026.100184_bib0069","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1093\/rheumatology\/keaa647","article-title":"Different treatment options for Takayasu arteritis patients with moderate-to-severe aortic regurgitation: long-term outcomes","volume":"60","author":"Cheng","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.athoracsur.2019.10.006","article-title":"Surgical treatment in patients with aortic regurgitation due to Takayasu arteritis","volume":"110","author":"Zhang","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ero.2026.100184_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2020.02.051","article-title":"Comparing the effects of different management strategies on long-term outcomes for significant coronary stenosis in patients with Takayasu arteritis","volume":"306","author":"Wang","year":"2020","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.ero.2026.100184_bib0072","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2017.02.041","article-title":"Outcomes of percutaneous coronary intervention and coronary artery bypass grafting in patients with Takayasu arteritis","volume":"241","author":"Yang","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ero.2026.100184_bib0073","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2020.10.031","article-title":"Clinical characteristics and outcomes of chronic heart failure in adult Takayasu arteritis: A cohort study of 163 patients","volume":"325","author":"Zhang","year":"2021","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.ero.2026.100184_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.948124","article-title":"Clinical characteristics and outcomes in patients with Takayasu arteritis coexisting with myocardial ischemia and neurological symptoms: a multicenter, long-term, follow-up study","volume":"9","author":"Huo","year":"2022","journal-title":"Front Cardiovasc Med."},{"issue":"10","key":"10.1016\/j.ero.2026.100184_bib0075","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3899\/jrheum.150097","article-title":"Clinical features and outcomes of Takayasu arteritis with neurological symptoms in China: a retrospective study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0076","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3899\/jrheum.2023-0629","article-title":"Aneurysmal disease in patients with Takayasu arteritis","volume":"51","author":"Lefebvre","year":"2024","journal-title":"J Rheumatol."},{"issue":"7","key":"10.1016\/j.ero.2026.100184_bib0077","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00296-017-3656-y","article-title":"Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients","volume":"37","author":"Rosa Neto","year":"2017","journal-title":"Rheumatol Int."},{"issue":"20","key":"10.1016\/j.ero.2026.100184_bib0078","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0079","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0080","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0081","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","article-title":"A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of sirukumab in the treatment of giant cell arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatol Ther."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0082","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis","volume":"25","author":"Schmidt","year":"2023","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0083","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ero.2026.100184_bib0084","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.ero.2026.100184_bib0086","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","article-title":"Treatment failure in giant cell arteritis","volume":"80","author":"Unizony","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"10.1016\/j.ero.2026.100184_bib0087","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","article-title":"New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension","volume":"61","author":"Stone","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0088","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.42405","article-title":"The effects of daily prednisone and tocilizumab on hemoglobin a(1c) during the treatment of giant cell arteritis","volume":"75","author":"Patel","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0089","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.reuma.2023.09.011","article-title":"Effect of combined treatment with prednisone and methotrexate versus prednisone alone over laboratory parameters in giant cell arteritis","volume":"20","author":"Perez-Sancristobal","year":"2024","journal-title":"Reumatol Clin (Engl Ed)."},{"key":"10.1016\/j.ero.2026.100184_bib0090","first-page":"suppl 9","article-title":"Anakinra in giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial [abstract]","volume":"76","author":"de Boysson","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0091","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","article-title":"Does leflunomide have a role in giant cell arteritis? An open-label study","volume":"38","author":"Ho\u010devar","year":"2019","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.ero.2026.100184_bib0092","article-title":"Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study","volume":"9","author":"Kramari\u010d","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0093","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3899\/jrheum.180429","article-title":"Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study","volume":"46","author":"Koster","year":"2019","journal-title":"J Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0094","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.14004","article-title":"Immunosuppressive therapy (methotrexate or cyclophosphamide) in combination with corticosteroids in the treatment of giant cell arteritis: comparison with corticosteroids alone","volume":"64","author":"Carbonella","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009742.2019.1575980","article-title":"Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival","volume":"48","author":"Tengesdal","year":"2019","journal-title":"Scand J Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0096","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/WNO.0000000000001220","article-title":"The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis","volume":"41","author":"Jogimahanti","year":"2021","journal-title":"J Neuroophthalmol."},{"key":"10.1016\/j.ero.2026.100184_bib0097","first-page":"151","article-title":"Tocilizumab vs methotrexate in a cohort of patients affected by active gca: a comparative clinical and ultrasonographic study","volume":"17","author":"Grazzini","year":"2023","journal-title":"Biologics"},{"issue":"8","key":"10.1016\/j.ero.2026.100184_bib0098","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s11739-024-03722-4","article-title":"Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres","volume":"19","author":"Quartuccio","year":"2024","journal-title":"Intern Emerg Med."},{"key":"10.1016\/j.ero.2026.100184_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152508","article-title":"Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center","volume":"68","author":"Nielsen","year":"2024","journal-title":"Semin Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0100","first-page":"829","article-title":"Optimisation of tocilizumab therapy in giant cell arteritis. a multicentre real-life study of 471 patients","volume":"41","author":"Calder\u00f3n-Goercke","year":"2023","journal-title":"Clin Exp Rheumatol."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-023-05527-8","article-title":"Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis","volume":"44","author":"Tsalapaki","year":"2024","journal-title":"Rheumatology int."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0102","doi-asserted-by":"crossref","first-page":"rkaa024","DOI":"10.1093\/rap\/rkaa024","article-title":"Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis","volume":"4","author":"Karabayas","year":"2020","journal-title":"Rheumatol Adv Pract."},{"key":"10.1016\/j.ero.2026.100184_bib0103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/rmdopen-2023-003301","article-title":"Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study","volume":"9","author":"Mensch","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2026.100184_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152351","article-title":"Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study","volume":"64","author":"Muratore","year":"2024","journal-title":"Semin Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.ero.2026.100184_bib0105","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","article-title":"Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study","volume":"5","author":"Unizony","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/rheumatology\/kead215","article-title":"Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study","volume":"63","author":"Muratore","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0107","doi-asserted-by":"crossref","first-page":"rkaa069","DOI":"10.1093\/rap\/rkaa069","article-title":"Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis","volume":"4","author":"Karabayas","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.ero.2026.100184_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152192","article-title":"Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis","volume":"60","author":"Lavergne","year":"2023","journal-title":"Semin Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.ero.2026.100184_bib0109","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"9","key":"10.1016\/j.ero.2026.100184_bib0110","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3899\/jrheum.200952","article-title":"Real-world risk of relapse of giant cell arteritis treated with tocilizumab: a retrospective analysis of 43 patients","volume":"48","author":"Cl\u00e9ment","year":"2021","journal-title":"J Rheumatol."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0111","doi-asserted-by":"crossref","first-page":"rkac017","DOI":"10.1093\/rap\/rkac017","article-title":"Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup","volume":"6","author":"Cronin","year":"2022","journal-title":"Rheumatol Adv Pract."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0112","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/mr\/road074","article-title":"A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan","volume":"34","author":"Harigai","year":"2024","journal-title":"Mod Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0113","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3899\/jrheum.2024-0612","article-title":"Tocilizumab (TCZ) for giant cell arteritis: clinical outcomes following relapses and tcz discontinuation due to adverse events","volume":"52","author":"Nagase","year":"2025","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ero.2026.100184_bib0114","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2018.06.008","article-title":"Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study","volume":"57","author":"Samson","year":"2018","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.ero.2026.100184_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/rmdopen-2020-001417","article-title":"Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool","volume":"6","author":"Sebastian","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/03009742.2021.1889025","article-title":"Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study","volume":"51","author":"Tomelleri","year":"2022","journal-title":"Scand J Rheumatol."},{"issue":"12","key":"10.1016\/j.ero.2026.100184_bib0117","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1093\/rheumatology\/kead604","article-title":"Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England","volume":"63","author":"Quick","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0118","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0119","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13075-024-03314-9","article-title":"Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature","volume":"26","author":"Loricera","year":"2024","journal-title":"Arthritis Res Ther."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0120","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0121","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res."},{"issue":"9","key":"10.1016\/j.ero.2026.100184_bib0122","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ero.2026.100184_bib0123","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/rheumatology\/keaa196","article-title":"Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis","volume":"59","author":"Ponte","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ero.2026.100184_bib0124","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2021-220306","article-title":"Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis","volume":"80","author":"Ponte","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/rheumatology\/kex341","article-title":"The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ero.2026.100184_bib0126","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard-2023-223895","article-title":"Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients","volume":"82","author":"Monti","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0127","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semarthrit.2019.09.008","article-title":"Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: a case-control study","volume":"50","author":"Dumont","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ero.2026.100184_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1188073","article-title":"Giant cell arteritis with vertebral artery involvement-baseline characteristics and follow-up of a monocentric patient cohort","volume":"14","author":"Pr\u00fcnte","year":"2023","journal-title":"Front Neurol."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0129","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2020.11.003","article-title":"Prevalence and prognostic factors for aortic dilatation in giant cell arteritis - a longitudinal study","volume":"51","author":"Jud","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.ero.2026.100184_bib0130","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221113747","article-title":"Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients","volume":"14","author":"Loricera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"10.1016\/j.ero.2026.100184_bib0131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2024.06.013","article-title":"Effectiveness of tocilizumab in aortitis and aneurysms associated with giant cell arteritis","volume":"129","author":"Mart\u00edn-Guti\u00e9rrez","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0132","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/rheumatology\/keae459","article-title":"The use of intravenous methylprednisolone in giant cell arteritis: a population-based study","volume":"64","author":"Henningson","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0133","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RHU.0000000000001051","article-title":"Vascular presentation and outcomes of patients with giant cell arteritis and isolated symptomatic limb involvement","volume":"26","author":"de Boysson","year":"2020","journal-title":"J Clin Rheumatol."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0134","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000426","article-title":"Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study","volume":"3","author":"Cutolo","year":"2017","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00296-014-3105-0","article-title":"Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment","volume":"35","author":"Viapiana","year":"2015","journal-title":"Rheumatol Int."},{"issue":"suppl 9","key":"10.1016\/j.ero.2026.100184_bib0136","article-title":"Results of a one year randomized double-blind placebo-controlled trial with methotrexate 25 mg per week for recently diagnosed polymyalgia rheumatica [abstract]","volume":"76","author":"Bolhuis","year":"2024","journal-title":"Rheu Arthritis."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0137","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.ero.2026.100184_bib0138","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA."},{"issue":"10","key":"10.1016\/j.ero.2026.100184_bib0139","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.43221","article-title":"Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumatica","volume":"77","author":"Chevet","year":"2025","journal-title":"Arthritis Rheumatol."},{"issue":"14","key":"10.1016\/j.ero.2026.100184_bib0140","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0141","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","article-title":"Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"7","author":"Saraux","year":"2025","journal-title":"Lancet Rheumatol."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0143","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00296-020-04783-2","article-title":"Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study","volume":"41","author":"Marsman","year":"2021","journal-title":"Rheumatol Int."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0144","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","article-title":"1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial","volume":"5","author":"Bolhuis","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00259-023-06557-x","article-title":"[(18)F]FDG PET\/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica","volume":"51","author":"Allard","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.ero.2026.100184_bib0146","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"10.1016\/j.ero.2026.100184_bib0147","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.43129","article-title":"Efficacy, safety, pharmacokinetics, and immunogenicity of ABBV-154 in adults with glucocorticoid-dependent polymyalgia rheumatica: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"77","author":"Spiera","year":"2025","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0148","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","article-title":"Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database","volume":"38","author":"Albrecht","year":"2018","journal-title":"Rheumatol Int."},{"issue":"7","key":"10.1016\/j.ero.2026.100184_bib0149","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/RHU.0000000000000701","article-title":"Clinical improvement according to rapid3 in patients with polymyalgia rheumatica: a longitudinal analysis from routine care","volume":"24","author":"Castrejon","year":"2018","journal-title":"J Clin Rheumatol."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10067-018-3988-3","article-title":"Therapeutic response to prednisone in relation to age in polymyalgia rheumatica: a comparison study","volume":"37","author":"Charpentier","year":"2018","journal-title":"Clin Rheumatol."},{"issue":"36","key":"10.1016\/j.ero.2026.100184_bib0151","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.3346\/jkms.2018.33.e241","article-title":"Characteristics of Korean patients with polymyalgia rheumatica: a single locomotive pain clinic cohort study","volume":"33","author":"Do","year":"2018","journal-title":"J Korean Med Sci."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0152","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/s41598-021-85857-4","article-title":"Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis","volume":"11","author":"Emamifar","year":"2021","journal-title":"Sci Rep."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0153","doi-asserted-by":"crossref","first-page":"rkab091","DOI":"10.1093\/rap\/rkab091","article-title":"Clinical presentation and treatment response in patients with polymyalgia rheumatica and giant cell arteritis during a 40-week follow-up","volume":"5","author":"Emamifar","year":"2021","journal-title":"Rheumatol Adv Pract."},{"issue":"7S Suppl 2","key":"10.1016\/j.ero.2026.100184_bib0154","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/RHU.0000000000001414","article-title":"Usefulness of methotrexate in the reduction of relapses and recurrences in polymyalgia rheumatica: an observational study","volume":"26","author":"de la Torre","year":"2020","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.ero.2026.100184_bib0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jcm10132948","article-title":"Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study","volume":"10","author":"Izumi","year":"2021","journal-title":"J Clin Med."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0156","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5606\/ArchRheumatol.2018.6418","article-title":"Mizoribine is as effective as methotrexate for the treatment of polymyalgia rheumatica: a retrospective case series analysis","volume":"33","author":"Shiraishi","year":"2018","journal-title":"Arch Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0157","doi-asserted-by":"crossref","first-page":"rkae033","DOI":"10.1093\/rap\/rkae033","article-title":"Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica","volume":"8","author":"Vinicki","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"10.1016\/j.ero.2026.100184_bib0158","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/rheumatology\/kead426","article-title":"Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study","volume":"63","author":"Assaraf","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ero.2026.100184_bib0159","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ero.2026.100184_bib0160","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00259-015-3287-z","article-title":"Value of (18)F-FDG PET\/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment","volume":"43","author":"Palard-Novello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"10.1016\/j.ero.2026.100184_bib0161","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/ggi.13460","article-title":"Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients","volume":"18","author":"Quartuccio","year":"2018","journal-title":"Geriatr Gerontol Int."},{"issue":"3","key":"10.1016\/j.ero.2026.100184_bib0162","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3899\/jrheum.180324","article-title":"Permanent discontinuation of glucocorticoids in polymyalgia rheumatica is uncommon but may be enhanced by amino bisphosphonates","volume":"46","author":"Giollo","year":"2019","journal-title":"J Rheumatol."},{"issue":"2","key":"10.1016\/j.ero.2026.100184_bib0163","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10067-022-06415-5","article-title":"Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box","volume":"42","author":"Misra","year":"2023","journal-title":"Clin Rheumatol."},{"issue":"1","key":"10.1016\/j.ero.2026.100184_bib0164","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/BOR.0000000000001051","article-title":"Giant cell arteritis: update on pathogenesis and clinical implications","volume":"37","author":"Ibrahim","year":"2025","journal-title":"Curr Opin Rheumatol."},{"issue":"6","key":"10.1016\/j.ero.2026.100184_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103328","article-title":"The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature review","volume":"22","author":"Sch\u00e4fer","year":"2023","journal-title":"Autoimmun Rev."},{"issue":"11","key":"10.1016\/j.ero.2026.100184_bib0166","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"5","key":"10.1016\/j.ero.2026.100184_bib0167","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1093\/rheumatology\/keae013","article-title":"Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis","volume":"63","author":"Misra","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ero.2026.100184_bib0168","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103917","article-title":"The fragility of randomized controlled trials in large vessel vasculitis","volume":"24","author":"Misra","year":"2025","journal-title":"Autoimmun Rev."}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:31:20Z","timestamp":1790343080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126000832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":168,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3050708126000832"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.100184","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review to inform the 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis: management of disease including relapse and complications","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.100184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100184"}}